SNG.L - Synairgen plc

LSE - LSE Delayed Price. Currency in GBp
-0.75 (-5.50%)
At close: 4:30PM GMT
Stock chart is not supported by your current browser
Previous Close13.62
Bid0.00 x 0
Ask0.00 x 0
Day's Range12.30 - 13.75
52 Week Range6.98 - 32.00
Avg. Volume223,383
Market Cap11.763M
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Synairgen plc (AIM:SNG): How Does It Impact Your Portfolio?
    Simply Wall St.2 months ago

    Synairgen plc (AIM:SNG): How Does It Impact Your Portfolio?

    If you are a shareholder in Synairgen plc’s (AIM:SNG), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • Reuters8 months ago

    AstraZeneca aims to escape drug sales trough in second half

    AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Chief Executive Pascal Soriot believes 2017 will mark the trough for the British group, as it starts to put generic losses behind it and builds up sales of recently launched and experimental cancer medicines. Industry analysts, on average, had forecast revenue of $5.4 billion and earnings of 82 cents, according to Thomson Reuters data.

  • We're sorry this is all we were able to find about this topic.